
References

1. Kaufman PL.; Alm A. Development and structure of the retina. *Adler's Physiology Of The Eye*. 3rd ed; 2003:338-339.
2. Schiller PH, Malpeli JG. Properties and tectal projections of monkey retinal ganglion cells. *J Neurophysiol*. 1977;428.
3. Stamper RL, Lieberman MF, Drake MV. Optic nerve anatomy and pathophysiology. *Becker-Shaffer's Diagnosis and Therapy of the Glaucomas*. 8th ed; 2009:143-153.
4. Minckler DS. The organization of nerve fiber in the primate optic nerve head. *Arch Ophthalmol*. 1980;98:1630.
5. Phelps C. Effect of myopia on prognosis in treated primary open-angle glaucoma. *Am J Ophthalmol*. 1982;93:622.
6. Burgoyne C, Downs JJ. Premise and prediction how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. *J Glaucoma*. 2008;17:318-328.
7. Quigley H; et al. Morphologic changes in the lamina cribrosa correlated with neural loss in open angle glaucoma. *Am J Ophthalmol*. 1983;95:673.
8. Clark A; et al. Cell biology of the human lamina cribrosa. In: Drance S, Anderson D, editors: *Optic nerve in glaucoma*, Amsterdam/New York, Kugler. 1995.
9. Tezel G, Wax M. Glial modulation of retinal ganglion cell death in glaucoma. *J Glaucoma*. 2003;12:63.
10. Tezel G; Hernandez M; Wax M. In vitro evaluation of reactive astrocyte migration, a component of tissue remodeling in glaucomatous optic nerve head, Glia. *J Glaucoma*. 2001;34:178.
11. Quigley H, Pease ME, Thibault D. Change in the appearance of elastin in the lamina cribrosa of glaucomatous optic nerve heads. *Graefes Arch Clin Exp Ophthalmol*. 1994;32:257.
12. Zeimer R. Biomechanical properties of the optic nerve head. In: Drance S, Anderson D, editors: *Optic nerve in glaucoma*, Amsterdam/New York, Kugler. 1995.
13. Quigley H, Addicks E. Regional differences in the structure of the lamina cribrosa and their reaction to glaucomatous nerve damage. *Arch Ophthalmol*. 1981;99:137.
14. Quigley H, Addicks E. Overview and introduction to session on connective tissue of the optic nerve in glaucoma. In: Drance S, Anderson D, editors: *Optic nerve in glaucoma*, Amsterdam/New York, Kugler. 1995.
15. Jonas J, Berenshtein E, Holbach L. Lamina cribrosa thickness and spatial relationships between intraocular space and cerebrospinal fluid space in highly myopic eyes. *Invest Ophthalmol Vis Sci*. 2004;45:2660.
16. Wang L; et al. Immunohistologic evidence for retinal glial cell changes in human glaucoma. *Invest Ophthalmol Vis Sci*. 2002;43:1088.
17. Kaufman PL, Alm A. Optic Nerve. *Adler's Physiology Of The Eye*. 10th ed; 2003:619-622.
18. Morgan W. The influence of cerebrospinal fluid pressure on the lamina cribrosa tissue pressure gradient. *Invest Ophthalmol Vis Sci*. 1995;36:1163.

19. Morgan W, Yu D, Balaratnasingam C. The role of cerebrospinal fluid pressure in glaucoma pathophysiology: the dark side of the optic disc. *J Glaucoma*. 2008;17:408-413.
20. Berdahl J, Allingham R, Johnson D. Cerebrospinal fluid pressure is decreased in primary open-angle glaucoma. *Ophthalmology*. 2008;115:763–768.
21. Pasquale L. Low intracranial pressure :A tipping point in our understanding of primary open-angle glaucoma?,. *Ophthalmology*. 2008;115:761–762.
22. Levin L. Relevance of the site of injury of glaucoma to neuroprotective strategies. *Surv Ophthalmol*. 2001;45:S243–S273.
23. Haefliger I, Fleischhauer J, Flammer J. In glaucoma,should enthusiasm about neuroprotection be tempered by the experience obtained in other neurodegenerative disorders? *Eye*. 2000;14:464.
24. Auld D, Robitaille R. Glial cells and neurotransmission: an inclusive view of synaptic function. *Neuron*. 2003;40:389-400.
25. Neufeld A, Liu B. Glaucomatous optic neuropathy: when glia misbehave. *Neuroscientist*. 2003;9:485.
26. Chidlow G; Wood JP; Casson RJ. Pharmacological neuroprotection for glaucoma. *Drugs*. 2007;67:726-759.
27. Miguel-Hidalgo JJ; Alvarez XA; Cacabelos R; Quack G. Neuroprotection by memantine against neurodegeneration induced by betaamyloid. *Brain Res*. 2002;958:210-221.
28. Guo L; Salt TE; Luong V; et al. Targeting amyloid-beta in glaucoma treatment. *Proc Natl Acad Sci USA*. 2007;104:13444-9.
29. Yucel YH; Gupta N, Zhang Q, Mizisin AP, et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. *Arch Ophthalmol*. 2006;124:217-225.
30. Maass A; Von Leithner PL, et al. Assessment of rat and mouse RGC apoptosis imaging in vivo with different scanning laser ophthalmoscopes. *Curr Eye Res*. 2007;32:851-861.
31. Guo L, Salt TE, Maass A. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. *Invest Ophthalmol Vis Sci*. 2006;47:626-633.
32. Hare WA; WoldeMussie E, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. *Invest Ophthalmol Vis Sci*. 2004;45:2625-39.
33. WoldeMussie, E; Yoles E, Schwartz M, et al. Neuroprotective effect of memantine in different retinal injury models in rats. *J Glaucoma*. 2002;11:474-480.
34. Dreyer EB; Zurakowski D, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. *Arch Ophthalmol*. 1996;114:299-305.
35. Brooks DE, Garcia GA. Vitreous body glutamate concentration in dogs with glaucoma. *Am J Vet Res*. 1997;58:864-7.
36. Wamsley S; Gabelt B T;et al. Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. *Arch Ophthalmol*. 2005;123:64-70.
37. Salt TE, Cordeiro MF. Glutamate excitotoxicity in glaucoma: throwing the baby out with

- the bathwater?. *Eye*. 2006;20:730-1.
38. Fletcher EL; Hack I; et al. Synaptic localization of NMDA receptor subunits in the rat retina. *J Comp Neurol*. 2000;420:98-112.
39. Cheung W, Guo L, Cordeiro MF. Neuroprotection in Glaucoma. *Optom Vis Sci*. 2008;85:406-416.
40. Dasari VR; Veeravalli KK; et al. Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway. *Neurobiology of Disease*. 2008;32:486-498.
41. Arien-Zakay H; Lecht S; Nagler A; et al. Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors. *Experimental Neurology*. 2009;216:83-94.
42. Danesh-Meyer HV, Levin LA. Neuroprotection: Extrapolating from Neurologic Diseases to the Eye. *Am J Ophthalmol*. 2009;148:186–191.
43. Nakamizo T; Kawamata J; et al. Stimulation of nicotinic acetylcholine receptor protects motor neurons. *Biochem. Biophys. Res. Commun*. 2005;330:1285e1289.
44. Keiger CJ; Prevette D; et al. Developmental expression of nicotinic receptors in the chick and human spinal cord. *J. Comp. Neurol*. 2003;455:86-99.
45. Wehrwein E; Thompson SA; et al. Acetylcholine neuroprotection of adult pig retinal ganglion cells from glutamate induced excitotoxicity. *Invest. Ophthalmol. Vis. Sci*. 2004;45:1531-43.
46. Thompson SA, O S. Acetylcholine neuroprotection against glutamate-induced excitotoxicity in adult pig retinal ganglion cells is partially mediated through alpha 4 nAChRs. *Experimental Eye Research*. 2006;5:1135-1145.
47. Halaris A, Plietz J. Agmatine: metabolic pathway and spectrum of activity in brain. *CNS Drugs*. 2007;21:885–900.
48. Hartwick AT. Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy. *Optom. Vis. Sci.*. 2001;78:85-94.
49. Garcí'a-Campos J, Villena A, Dí'az F. Morphological and functional changes in experimental ocular hypertension and role of neuroprotective drugs. *Histol. Histopathol*. 2007;22:1399–1411.
50. Hong S, Kim CY, Lee JE, Seong GJ. Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line. *BMC Neurosci.*. 2007;8:81.
51. Hong S, Park K, Kim CY, Seong GJ. Agmatine inhibits hypoxia-induced TNF-alpha release from cultured retinal ganglion cells. *Biocell*. 2008;32:201–205.
52. Hong S, Kim CY, Lee JE, Seong GJ. Agmatine protects cultured retinal ganglion cells from tumor necrosis factor-alpha-induced apoptosis. *Life Sci.*. 2009;84:28-32.
53. Iizuka, Y; et al. Agmatine pretreatment protects retinal ganglion cells (RGC-5 cell line) from oxidative stress in vitro. *Biocell*. 2008;32:245-250.
54. Hong S, Kim CY, Lee WS, Shim J, Yeom HY, Seong GJ. Ocular hypotensive effects of

- topically administered agmatine in a chronic ocular hypertensive rat model. *Experimental Eye Research*. 2010;90:97-103.
55. Hains BC, Waxman SG. Neuroprotection by Sodium Channel Blockade with Phenytoin in an Experimental Model of Glaucoma. *Invest Ophthalmol Vis Sci*. 2005;46:4164–4169.
56. Schwartz M. Physiological approaches to neuroprotection. Boosting of protective autoimmunity. *Surv Ophthalmol*. 2001;3:S256–S260.
57. Schwartz M. Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture. *Invest Ophthalmol Vis Sci*. 2003;44:1407–11.
58. Ben Simon, G J; Bakalash, S; et al. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy. *Am J Ophthalmol*. 2006;141:1105-11.
59. Kipnis J; Yoles E; et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. *Proc Natl Acad Sci USA*. 2000;97:7446–51.
60. Botchkina GI; Meistrell ME III; et al. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. *Mol Med*. 1997;3:765-781.
61. Tezel G; et al. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. *Invest Ophthalmol Vis Sci*. 2001;42:1787-94.
62. Laengle UW; Markstein R; et al. Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-alpha release in vitro from activated rat mast cells. *Exp Eye Res*. 2006;83:1335-9.
63. Laengle UW; Trendelenburg AU; et al. GLC756 decreases TNF-alpha via an alpha2 and beta2 adrenoceptor related mechanism. *Exp Eye Res*. 2006;83:1246-51.
64. Harper MM; Adamson L ; Blits B ; et al. Brain-derived neurotrophic factor released from engineered mesenchymal stem cells attenuates glutamate- and hydrogen peroxide-mediated death of staurosporine-differentiated RGC-5 cells. *Experimental Eye Research*. 2009;89:538-548.
65. Fu, Q L; Li, X; Wu, W; et al. Combined effect of brain-derived neurotrophic factor and lingo-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. *Neuroscience*. 2009;162:375–382.
66. Wood JPM; Schmidt KG; et al. The β -adrenoceptors antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. *Experimental Eye Research*. 2003;76:505-516.
67. Hernandez M, Urcola JH, Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. *Experimental Eye Research*. 2008;86:798-806.
68. Watanabe M, Tokita Y, Yata Y. Axonal regeneration of cat retinal ganglion cells is promoted by nipradilol, an anti-glaucoma drug. *Neuroscience*. 2006;140:517-528.
69. Tsai RK; Chang CH; Wang HZ. Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in neurodegeneration after optic nerve

- crush in rats. *Exp. Eye Res.*. 2008;87:242-250.
70. Naito T; Goto K; Morioka S; et al. Administration of granulocyte colony-stimulating factor facilitates the regenerative process of injured mice skeletal muscle via the activation of Akt/GSK3 α signals. *Eur. J. Appl. Physiol.*. 2009;105:643-651.
71. Tsai RK ; Chang CH; et al. Anti-apoptotic effects of human granulocyte colony-stimulating factor (G-CSF) on retinal ganglion cells after optic nerve crush are PI3K/AKT-dependent. *Experimental Eye Research*. 2010:1-9.
72. Young MJ, Klassen HJ. Polymeric delivery of neuroprotective compounds to the vitreous cavity: a potential treatment for glaucoma. *ARCH SOC ESP OFTALMOL*. 2006;81:429-432.
73. Guo L, Cordeiro MF. Assessment of neuroprotection in the retina with DARC. *Progress in Brain Research*. 2008;173:437-450.